A study analyzing the clinical, histopathological and immunological profile of patients with cutaneous vasculitis: IgA vasculitis and non-IgA vasculitis
DOI:
https://doi.org/10.66344/jpad.v33i4.2521Keywords:
Vasculitis, IgA vasculitis, Purpuras, Leukocytoclastic vasculitisAbstract
Background Skin is frequently involved in small-vessel vasculitis. Based on immunofluorescence studies, it can be IgA type (Henoch-Schoenlein purpura) or IgA-negative type i.e. leukocytoclastic vasculitis. Clinically, palpable purpura is the hallmark of the disease. Both subtypes can be associated with variable systemic involvement.
Objective To compare the clinical, histopathological and immunological profile of patients with IgA and IgA-negative vasculitis with special reference to renal involvement.
Methods Seventy-five patients presenting to the outpatient clinic of a tertiary care hospital with a clinical diagnosis of palpable purpura were enrolled in the study. All patients had a thorough clinical examination and detailed history, and results were documented on a pre-made proforma.
Results On direct immunofluorescence findings, 40 patients had IgA vasculitis and 35 IgA-negative vasculitis. The mean age of presentation was 38.8 years in IgA vasculitis and 54.3 years in IgA-negative vasculitis. IgA vasculitis presented with frequent cutaneous (n=27, 67.5%, itching or pain) and systemic symptoms (n=18, 45%, abdominal and joints) seventeen (42.5%) as compared to IgA-negative subgroup (25.4% and 11.4%, respectively). Morphologically, palpable purpura was seen in both groups, but 11.4% patients in IgA-negative vasculitis group presented with ulcerated lesions. Patients of both groups had vessel wall fibrin deposition and necrosis, inflammatory infiltrate in the vessel wall, erythrocyte extravasation, unclear dust and endothelial swelling in descending frequencies. Complement 3 (C3) was the commonest immunoreactant (n=71; 94.7%) followed by fibrinogen (n=59; 78.7%) and immunoglobulin A (IgA) [n=40; 53.3%]. Abnormal urine microscopy findings were detected in (n=28; 70%) patients with IgA vasculitis and in (n=2; 5.7%) with IgA-negative vasculitis. Serum creatinine was raised in 12 (30%) patients with IgA vasculitis and 7 (20%) patients with IgA-negative vasculitis. Other laboratory tests had similar frequency in two groups.
Conclusion IgA vasculitis was seen in a relatively younger age group in comparison to IgA-negative vasculitis. C3 was the commonest immunoreactant staining the blood vessel wall followed by fibrinogen and IgA. Renal involvement occurred more frequently in the IgA vasculitis.
References
1. Alpsoy E. Cutaneous vasculitis; An algorithmic approach to diagnosis. Front Med (Lausanne). 2022;9:1012554. doi: 10.3389/fmed.2022.1012554. PMID: 36213632; PMCID: PMC9532537.31
2. Shpadaruk V, Harman KE. Cutaneous vasculitis, connective tissue diseases, and urticaria. In: Firth J, Conlon C, Cox T, editors. Oxford Textbook of Medicine, 6 edn. Oxford, UK; 2020; Pg.5639-5674. Online edn, Oxford Academic, 1 Jan. 2020, available from
https://doi.org/10.1093/med/9780198746690.003.0556. Accessed 13 March 2023.
3. Reamy BV, Servey JT, Williams PM. Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review. Am Fam Physician. 2020;102:229-33.
4. Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16:831–41.
5. Sams Jr WM, Claman HN, Kohler PF, McIntosh RM, Small P, Mass MF. Human necrotizing vasculitis. Immunoglobulins and complement in vessel walls of lesions and normal skin. Int J Dermatol. 1975;64:441-5.
6. Borges T, Gomes AR, Santos J, Silva S. Primary systemic vasculitides as the bridge in immune-mediated disorders: small vessels for autoimmunity, medium vessels for autoinflammation. Acta Reumatol Port. 2021;46(1):58-68.
7. Sais G, Vidaller A, Jucgla A, Servitje O, Condom E, Peyri J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134:309-15.
8. Van Hale, Gibson LE, Schroeter AL. Henoch Schonlein vasculitis: Direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol. 1986;15:665-70.
9. Barnadas MA, Perez E, Gich I, Llobet JM, Ballarín J, Calero F et al. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol. 2004;43:19-26.
10. Grunwald MH, Avinoach I, Amichai B, Halevy S. Leukocytoclastic vasculitis correlation between different histologic stages and direct immunofluorescence results. Int J Dermatol. 1997;36:349-52.
11. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis: sequential appearance of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol. 1977;69:477-84.
12. Eaf E, Callen JP. Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984;120(4):484-9. DOI:10.1001/archderm.120.4.484
13. Hodge SJ, Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol.1987;14(5):279-84.
doi: 10.1111/j.1600-0560.1987.tb00500.x.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Shafia Nisar Kakroo, Mohammad Ashraf Khan , Mirza Aumir Beg, Basit Kakroo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
